Diabetes drug could boost dialysis fluid removal and fight scarring
NCT ID NCT06913647
First seen Apr 05, 2026 · Last updated May 25, 2026 · Updated 7 times
Summary
This study tests whether canagliflozin, a diabetes medicine, can improve fluid removal and reduce scarring in the belly lining for 30 adults on peritoneal dialysis. Participants will take the drug or a placebo for 26 weeks each, then switch. The goal is to see if the drug helps dialysis work better and protects the membrane used for treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD (CHRONIC KIDNEY DISEASE) STAGE 5D are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Institute-McGill University Health Center
RECRUITINGMontreal, Quebec, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.